A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder-Reference-Cited by-同舟云学术

A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder

Published:2020-08 Issue:2 Volume:204 Page:247-253
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

DeCastro Guarionex J.¹,Sui Wilson²,Pak Jamie S.¹,Lee Shing M.³,Holder Dara⁴,Kates Max M.⁵,Virk Renu K.⁶,Drake Charles G.⁷,Anderson Christopher B.¹,James Bridget⁸,Abate-Shen Cory T.⁹,McKiernan James M.¹

Affiliation:

1. Department of Urology, Columbia University Irving Medical Center, New York, New York

2. Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee

3. Department of Biostatistics, Columbia University Mailman School of Public Health, New York, New York

4. Department of Urology, University of Wisconsin-Madison, Madison, Wisconsin

5. James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland

6. Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York

7. Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, New York

8. Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York

9. Irving Cancer Research Center, Columbia University Irving Medical Center, New York, New York

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection;European Urology;2024-08

2. Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor;Cancers;2024-07-17

3. Cisplatin-Based Combination Therapy for Enhanced Cancer Treatment;Current Drug Targets;2024-05

4. Experimental and New Approaches for Bladder Preservation in Intermediate and High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC);Research and Reports in Urology;2024-04

5. Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer;Cancers;2024-03-30